"Cellartis is a world-leading company with regard to competence above all in the field of pluripotent stem cells, and as such is a valuable resource in developing the right products for a rapidly growing market," says Magnus Nilsson, Vitrolife's CEO, who also points out that "stem cell culture is difficult and both Vitrolife and Cellartis have long experience of optimizing culture environments for sensitive cells."  

The financial scope of the agreement will not be made public.

Göteborg
October 8, 2009

Magnus Nilsson
CEO

Queries should be addressed to:  
Magnus Nilsson, CEO, phone +46 31 721 80 61.
Eva Nilsagård, CFO, phone +46 31 721 80 13.

____________________________________________________________________________

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.

The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 150 employees and the company's products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan. Production facilities are housed in Sweden and USA.  

The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.